Quadpill at Quarter Dose – A New First-Line Strategy in Hypertension
Quadpill at Quarter Dose – A New First-Line Strategy in Hypertension
Medscape Cardiology, February 13, 2026
QUARTET Trial -Published in The Lancet
• Ultra–low-dose quadpill (¼ standard dose each: irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg) initiated from day one in mild–moderate hypertension.
• QUARTET trial showed superior BP reduction (~6–7 mmHg additional systolic lowering) versus standard-dose monotherapy, without increased serious adverse events.
• Concept: early low-dose multidrug synergy may outperform stepwise escalation while maintaining tolerability
